These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain. Civiero L; Cirnaru MD; Beilina A; Rodella U; Russo I; Belluzzi E; Lobbestael E; Reyniers L; Hondhamuni G; Lewis PA; Van den Haute C; Baekelandt V; Bandopadhyay R; Bubacco L; Piccoli G; Cookson MR; Taymans JM; Greggio E J Neurochem; 2015 Dec; 135(6):1242-56. PubMed ID: 26375402 [TBL] [Abstract][Full Text] [Related]
3. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216 [TBL] [Abstract][Full Text] [Related]
4. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. Plowey ED; Cherra SJ; Liu YJ; Chu CT J Neurochem; 2008 May; 105(3):1048-56. PubMed ID: 18182054 [TBL] [Abstract][Full Text] [Related]
5. Contribution of GTPase activity to LRRK2-associated Parkinson disease. Tsika E; Moore DJ Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585 [TBL] [Abstract][Full Text] [Related]
6. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358 [TBL] [Abstract][Full Text] [Related]
9. Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. Stafa K; Tsika E; Moser R; Musso A; Glauser L; Jones A; Biskup S; Xiong Y; Bandopadhyay R; Dawson VL; Dawson TM; Moore DJ Hum Mol Genet; 2014 Apr; 23(8):2055-77. PubMed ID: 24282027 [TBL] [Abstract][Full Text] [Related]
10. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Su YC; Qi X Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973 [TBL] [Abstract][Full Text] [Related]
12. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749 [TBL] [Abstract][Full Text] [Related]
13. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. Sen S; Webber PJ; West AB J Biol Chem; 2009 Dec; 284(52):36346-36356. PubMed ID: 19826009 [TBL] [Abstract][Full Text] [Related]
14. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745 [TBL] [Abstract][Full Text] [Related]
15. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A. Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905 [TBL] [Abstract][Full Text] [Related]
16. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891 [TBL] [Abstract][Full Text] [Related]
17. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043 [TBL] [Abstract][Full Text] [Related]
18. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation. Schwab AJ; Ebert AD Stem Cell Reports; 2015 Dec; 5(6):1039-1052. PubMed ID: 26651604 [TBL] [Abstract][Full Text] [Related]
19. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. Ramonet D; Daher JP; Lin BM; Stafa K; Kim J; Banerjee R; Westerlund M; Pletnikova O; Glauser L; Yang L; Liu Y; Swing DA; Beal MF; Troncoso JC; McCaffery JM; Jenkins NA; Copeland NG; Galter D; Thomas B; Lee MK; Dawson TM; Dawson VL; Moore DJ PLoS One; 2011 Apr; 6(4):e18568. PubMed ID: 21494637 [TBL] [Abstract][Full Text] [Related]
20. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]